Julia Stingl
Impact in
- Oncology top 0.2%
- Cancer Cells and Metastasis
- Cancer-related Molecular Pathways
- Pharmacology top 0.05%
- Pharmacogenetics and Drug Metabolism
Papers in
- Pharmacology 48
- Pharmacogenetics and Drug Metabolism 48
- Treatment of Major Depression 10
-
- Pharmaceutical Practices and Patient Outcomes 17
- Co-authors
- Connie J. EavesJane E. VisvaderMark ShackletonFrançois VaillantCarlos CaldasPeter EirewJoanne T. EmermanGeoffrey J. Lindeman
- Journals
- Pharmacogenomics (10 papers)PLoS ONE (9 papers)British Journal of Clinical Pharmacology (8 papers)Breast Cancer Research (8 papers)Clinical Pharmacology & Therapeutics (8 papers)
- Partner nations
- GermanyUnited KingdomUnited States
In The Last Decade
Julia Stingl
197 papers receiving 11.7k citations
Hit Papers
Peers
Comparison fields: 5 of 163
- Oncology 5.6k
- Pharmacology 1.8k
- Cancer Research 1.8k
- Biological Psychiatry 273
- Molecular Biology 5.0k
Countries citing papers authored by Julia Stingl
This map shows the geographic impact of Julia Stingl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julia Stingl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julia Stingl more than expected).
Fields of papers citing papers by Julia Stingl
This network shows the impact of papers produced by Julia Stingl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julia Stingl. The network helps show where Julia Stingl may publish in the future.
Co-authors
The 25 scholars most cited alongside Julia Stingl, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 2 | |
| 3 | 2025 | 0 | |
| 4 | 2024 | 1 | |
| 5 | 2023 | 4 | |
| 6 | 2023 | 0 | |
| 7 | 2023 | 8 | |
| 8 | 2023 | 7 | |
| 9 | 2022 | 5 | |
| 10 | 2022 | 2 | |
| 11 | 2021 | 7 | |
| 12 | 2021 | 2 | |
| 13 | 2020 | 9 | |
| 14 | 2020 | 32 | |
| 15 | 2020 | 20 | |
| 16 | Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update | 2017 | 57 |
| 17 | 2015 | 320 | |
| 18 | Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors | 2015 | 51 |
| 19 | 2014 | 38 | |
| 20 | 2012 | 59 |
About Julia Stingl
Julia Stingl is a scholar working on Pharmacology, Geriatrics and Gerontology, Toxicology, Biological Psychiatry and Oncology, having authored 210 papers that have together received 11.9k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (48 papers), Cancer Cells and Metastasis (35 papers), Pharmaceutical studies and practices (22 papers), Pharmaceutical Practices and Patient Outcomes (17 papers), Pharmacovigilance and Adverse Drug Reactions (14 papers), Pharmacological Effects and Toxicity Studies (11 papers), Treatment of Major Depression (10 papers) and Cancer Treatment and Pharmacology (8 papers). The work is most often cited by research in Oncology (5.6k citations), Pharmacology (1.8k citations), Cancer Research (1.8k citations), Biological Psychiatry (273 citations) and Molecular Biology (5.0k citations). Julia Stingl has collaborated with scholars based in Germany, United Kingdom and United States. Frequent co-authors include Connie J. Eaves, Jane E. Visvader, Mark Shackleton, François Vaillant, Carlos Caldas, Peter Eirew, Joanne T. Emerman, Geoffrey J. Lindeman, Marie-Liesse Asselin-Labat and Kaylene J. Simpson. Their work appears in journals such as Pharmacogenomics, PLoS ONE, British Journal of Clinical Pharmacology, Breast Cancer Research and Clinical Pharmacology & Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.